SGLT2 저해제/metformin 고정용량복합제의 국내 사용 현황
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 최하은 | - |
dc.contributor.author | 이지원 | - |
dc.contributor.author | 제남경 | - |
dc.contributor.author | 정경혜 | - |
dc.date.accessioned | 2022-05-18T00:40:19Z | - |
dc.date.available | 2022-05-18T00:40:19Z | - |
dc.date.issued | 2022-03 | - |
dc.identifier.issn | 1226-6051 | - |
dc.identifier.issn | 2508-786X | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/57751 | - |
dc.description.abstract | Background: The use of combination therapy and fixed-dose combination therapy is increasing for the treatment of type 2 diabetes. Sodium glucose cotransporter-2 inhibitor (SGLT2i) is a drug class used in combination with metformin. Methods: Type 2 diabetes patients on SGLT2i/metformin combination therapy were extracted from the 2019 Health Insurance Review & Assessment ServiceNational Patients Sample. On July 1, 2019, SGLT2i and metformin fixed-dose combination (SGLT2i/metformin FDC) and two-pill combination (TPC) groups were identified, and a chi-square test and multiple logistic regression were performed. Results: Of total 2,992 patients, 1,077 (36%) were prescribed SGLT2i/metformin FDC and 1,915 (64%) were prescribed TPC. We found that the most common comorbidities were in the order of dyslipidemia, gastrointestinal disease, and hypertension. Multiple logistic regression analysis showed that the use of SGLT2i/metformin FDC was lower than TPC in patients with diabetic neuropathy (OR=0.76, p=0.008). Clinic (OR=2.09, p | - |
dc.format.extent | 7 | - |
dc.language | 한국어 | - |
dc.language.iso | KOR | - |
dc.publisher | 한국임상약학회 | - |
dc.title | SGLT2 저해제/metformin 고정용량복합제의 국내 사용 현황 | - |
dc.title.alternative | Use of SGLT2 inhibitor/metformin fixed dose combination in Korea | - |
dc.type | Article | - |
dc.identifier.doi | 10.24304/kjcp.2022.32.1.13 | - |
dc.identifier.bibliographicCitation | 한국임상약학회지, v.32, no.1, pp 13 - 19 | - |
dc.identifier.kciid | ART002825256 | - |
dc.description.isOpenAccess | N | - |
dc.citation.endPage | 19 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 13 | - |
dc.citation.title | 한국임상약학회지 | - |
dc.citation.volume | 32 | - |
dc.publisher.location | 대한민국 | - |
dc.subject.keywordAuthor | Type 2 diabetes | - |
dc.subject.keywordAuthor | sodium glucose cotransporter-2 inhibitor | - |
dc.subject.keywordAuthor | SGLT2i/metformin fixed-dose combination | - |
dc.subject.keywordAuthor | two-pill combination | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.